EFTA00663598.pdf

From: To: Subject: Date: Attachments: Jeffrey Epstein <jeevaeation@gmail.com> Fwd: Introducing Leidos Health Wed, 23 Apr 2014 19:17:12 +0000 HRMP_ Fact _Sheet.pdf; Virtual_Biotech Phanna_lnitiative.pdf; Leidos_Case_Study_Translational_Research_Support.pdf; Leidosinsight_Stakeholder_Inclusion[2].pdf; Leidos_Capabilities_Program_Management[1].pdf Forwarded message From: Duenas, Martin A. Date: Tue, Apr 22, 2014 at 10:45 AM Subject: Introducing Leidos Health To: "jeffrey*jeffreyspstein.org" <jeffrey_kjeffreyspstein.org> > Dear Jeffrey, I write to introduce myself and my organization. I used to work at the Juvenile Diabetes Research Foundation (JDRF) and most recently; I was a founding member of the Patient-Centered Outcomes Research Institute (PCORI). At JDRF (www.jdrf.org), I managed the international grants portfolio as their National Director and COO of Research, as well as their patient/stakeholder program. I went to PCORI in Washington, DC to help startup the institute (www.pcori.org). At PCORI, I set up the organization strategic plan, policies and procedures, standard operating precedes, grants and program management, IT, and their patients/stakeholder program. I recently joined Leidos Health to develop a consulting practice to support organization like yours - see attached. I would welcome the opportunity to hear more about your organization so we may explore opportunities to work together. I am in NYC next week and I can stop by anytime. Next Tu, April 29, there will be a couple of Leidos Health Scientists with me, and if you have time, we welcome the opportunity to talk to you in person. I look forward to hearing from you. Thank you/Gracias, Martin Martin A. Duenas, MPA Director I Health Research Management Practice Managed Life Sciences cell (1): cell (2): I www.leidos.com/health EFTA00663598 This email and any attachments to it are intended only for the identified recipients. It may contain proprietary or otherwise legally protected information of Leidos. Any unauthorized use or disclosure of this communication is strictly prohibited. If you have received this communication in error, please notify the sender and delete or otherwise destroy the email and all attachments immediately. EFTA00663599